Evidence map›Paper›PMID 36982465›Full record

ArticleInternational journal of molecular sciences2023

HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS.

Alberto Cordero, Natàlia Muñoz-García, Teresa Padró, Gemma Vilahur, Vicente Bertomeu-González, David Escribano, Emilio Flores, Pilar Zuazola, Lina Badimon

Open access · goldFull text read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Alberto CorderoCardiology Department, Hospital Universitario de San Juan, 03550 Alicante, Spain.ORCID 0000-0003-0000-7109
Natàlia Muñoz-GarcíaCardiovascular-Program ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain.
Teresa PadróCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.ORCID 0000-0003-1921-954X
Gemma VilahurCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
Vicente Bertomeu-GonzálezUnidad de Investigación en Cardiología, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.
David EscribanoUnidad de Investigación en Cardiología, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.
Emilio FloresDepartamento de Análisis Clínicos, Hospital Universitario de San Juan, 03550 Alicante, Spain.ORCID 0000-0001-7524-0808
Pilar ZuazolaUnidad de Investigación en Cardiología, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.
Lina BadimonCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.ORCID 0000-0002-9162-2459
Hospital de Sant Pau · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESHospital Universitari Sant Joan D'Alacant · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESUniversitat Autònoma de Barcelona · ES

Funding

Centro de Investigación en Red en Enfermedades Cardiovasculares CB16/11/00226Centro de Investigación en Red en Enfermedades Cardiovasculares CB16/11/00411Centro de Investigación en Red en Enfermedades Cardiovasculares CB16/11/00420Government of Catalonia 2017 SGR 1480Instituto de Salud Carlos III FIS PI19/01687Ministry of Economy, Industry and Competitiveness AEI /10.13039/501100011033-[PID2019-107160RB-I00Ministry of Economy, Industry and Competitiveness PID2021-128891OB-I00Sociedad Española de Cardiología Investigación Clínica 2017
6 · The paper itself

Abstract

Patients admitted for acute coronary syndrome (ACS) usually have high cardiovascular risk scores with low levels of high-density lipoprotein cholesterol (HDL-C) and high low-density lipoprotein cholesterol (LDL-C) levels. Here, we investigated the role of lipoprotein functionality as well as particle number and size in patients with a first-onset ACS with on-target LDL-C levels. Ninety-seven patients with chest pain and first-onset ACS with LDL-C levels of 100 ± 4 mg/dL and non-HDL-C levels of 128 ± 4.0 mg/dL were included in the study. Patients were categorized as ACS and non-ACS after all diagnostic tests were performed (electrocardiogram, echocardiogram, troponin levels and angiography) on admission. HDL-C and LDL-C functionality and particle number/size by nuclear magnetic resonance (NMR) were blindly investigated. A group of matched healthy volunteers (

Indexed as

Acute Coronary SyndromeST Elevation Myocardial InfarctionChest PainCholesterolCholesterol, HDLCholesterol, LDLHumansLipoproteinsCholesterolCholesterol, HDLCholesterol, LDLLipoproteinsACScholesterol effluxHDL-CLDL-Clipoprotein functionalityNSTEMISTEMI

Identifiers

PMID36982465
PMCPMC10048810
OpenAlexW4324097486

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read41
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.